Scopio Labs

Executive Summary

Scopio Labs is an Israeli-based medical device company pioneering AI-powered full-field digital microscopy for hematology and oncology. Its platforms, the Scopio X100 and X100HT, replace traditional light microscopes by capturing 100x resolution whole-slide images of peripheral blood smears and bone marrow aspirates. The system enables remote review, automated cell morphology analysis, and faster turnaround times, addressing critical bottlenecks in clinical labs. With a commercial-stage product and a focus on improving diagnostic efficiency and accuracy, Scopio targets a growing market driven by demand for digital pathology and AI-assisted diagnosis. The company differentiates itself through its full-field imaging capability, which provides comprehensive morphological data without the need for multiple fields of view. Scopio’s technology has the potential to standardize hematopathology interpretation and expand access to expert analysis in remote settings. With a seasoned team and backing from strategic investors, Scopio is positioned for near-term growth through geographic expansion and regulatory clearances.

Upcoming Catalysts (preview)

• Q4 2026FDA clearance for expanded clinical indications (e.g., bone marrow aspirates)80% success
• Q2 2026Commercial partnership with major US diagnostic laboratory network60% success
• TBDSeries C funding round to accelerate sales and international expansion70% success